Application of Infliximab on inflammatory bowel disease in children
10.3760/cma.j.cn101070-20191116-01139
- VernacularTitle:英夫利昔单抗在儿童炎症性肠病中的应用
- Author:
Baihui FENG
1
;
Lingfen XU
Author Information
1. 中国医科大学附属盛京医院小儿消化内科，沈阳 110004
- From:
Chinese Journal of Applied Clinical Pediatrics
2020;35(19):1514-1517
- CountryChina
- Language:Chinese
-
Abstract:
Inflammatory bowel disease is a chronic and nonspecific intestinal disease that is mainly treated with drugs.At present, Infliximab (IFX) is the only biological agent applied for children with inflammatory bowel disease in China.It is essentially a biosynthetic chimeric monoclonal antibody, and can be combined with tumor necrosis factor-alpha(TNF-α) on T cells inhibition of inflammatory response through cytotoxicity and induction of lymphocyte apoptosis.IFX can induce remission in the short term and maintain remission in the long term.It can also promote mucosal repair, improve the quality of life and reduce complications.Clinical studies revealed that there were a proportion of patients who respond poorly or ineffectively to IFX treatment.Furthermore, due to the high cost of biological agents, bio generic drugs are gradually starting to be developed and applied.This article provided an overview of the application of IFX on inflammatory bowel disease in children.
